Skip to main content
. Author manuscript; available in PMC: 2019 Apr 15.
Published in final edited form as: Cancer Res. 2018 Sep 5;78(20):5877–5890. doi: 10.1158/0008-5472.CAN-18-1011

Figure 6. CDC34 promoted p21 degradation.

Figure 6.

(A-B). In CDC34 over-expressed MKN-45 cells and BGC-823 cells, the expression level of P21 was detected by western blotting.

(C-F). MKN-45 cells (C-D) and BGC-823 cells (E-F) transfected with CDC34 overexpression vector and control cells treated with Actinomycin D (5ug/ml) for the indicated periods of time. P21 mRNA levels were analyzed by RT-qPCR.

(G-J). MKN-45 cells (G-H) and BGC-823 cells (I-J) transfected with si-CDC34 and control cells treated with Actinomycin D (5ug/ml) for the indicated periods of time. P21 mRNA levels were analyzed by RT-qPCR.

(K-N). MKN-45 cells (K-L) and BGC-823 cells (M-N) transfected with CDC34 overexpression vector and control cells were treated with cycloheximide (CHX 5ug/ml) or vehicle for the indicated periods. P21 protein levels were analyzed by western blotting.

(O-P). MKN-45 cells (O) and BGC-823 cells (P) transfected with CDC34 overexpression vector and control cells were treated with MG132 (5 μM) or vehicle for 24 h. Cell lysates were analyzed by western blotting.

(Q). Western blotting analysis of the p21 in BGC-823 cells overexpressing HNF1A-AS1 or control cells with or without transient transfection withCDC34 siRNA.

ActD and CHX is respectively short for Actinomycin D and Cycloheximide. Three independent experiments were performed, and data are shown as mean ± SD.